Article Text

Download PDFPDF

P04.01 Volatile profiling using an eNose allows differentiation of volatile phases derived from serum, DC, or MLC culture supernatants from healthy or leukemic samples
  1. T Baudrexler1,
  2. T Boeselt2,
  3. S Bohlscheid1,
  4. L Li1,
  5. C Schmid3,
  6. A Rank3,
  7. J Schmohl4 and
  8. HM Schmetzer1
  1. 1University Hospital Munich LMU, Munich, Germany
  2. 2Phillipps-University Hospital of Marburg, Marburg, Germany
  3. 3University Hospital of Augsburg, Augsburg, Germany
  4. 4Diaconia Hospital Stuttgart, Stuttgart, Germany


Background Volatile organic compounds (VOCs) reflect the metabolism in healthy and pathological conditions. They can be collected easily in a noninvasive matter, directly measured by electronical nose (eNose) and might qualify as a systemic tool to monitor biomarkers related to disease.1 Myeloid leukemic blasts can be transformed into leukemia derived dendritic cells (DCleu) being able to improve (anti-leukemic) immune responses.2 To profile the immunological changes in healthy and acute myeloid leukemic (AML) patients’ ex vivo cell cultures, we correlated the cell biological data with the profiles of cell culture supernatants derived VOCs.

Materials and Methods DC/DCleu from leukemic or healthy whole blood (WB) were generated without (Control) or with immunomodulatory Kit M (Granulocyte-macrophage-colony-stimulating-factor (GM-CSF) + prostaglandin E1 (PGE1)) in dendritic cell cultures (DC culture). Kit pretreated/not pretreated WB was used to stimulate T cell enriched immunoreactive cells in mixed lymphocyte cultures (MLC culture). Leukemia-specific adaptive and innate immune cells were detected with degranulation assay (Deg) and an intracellular assay (InCyt). Anti-leukemic cytotoxicity was explored with a cytotoxicity fluorolysis assay (CTX). VOCs collected from DC- and MLC culture supernatants (with vs. without Kit M pretreatment and before vs. after culture) were measured by eNose.

Results Compared to Control (without treatment) a Kit M pretreated leukemia and healthy WB gave rise to higher frequencies of mature (leukemia derived) DC subtypes and activated and memory T cells after MLC. Moreover, antigen (leukemia) specific cells of several lines (innate and adaptive immunity cells) were induced giving rise to blast lysing cells. The eNose could significantly distinguish between healthy and leukemic patients’ serum-, DC- and MLC-culture supernatants derived volatile phases and could significantly separate several supernatants (with vs. without Kit M treatment, cultured vs. uncultured) derived VOCs within subgroups (healthy DC or leukemic DC or healthy MLC or leukemic MLC supernatants). Interestingly, the eNose could indicate a Kit M and culture associated effect.

Conclusions The eNose might be a prospective option for a deduction of a VOC based profiling strategy using serum or cell culture supernatants and could be a useful diagnostic tool to recognize AML illness.


  1. Biehl, W., Hattesohl, A., Jorres, R. A., et al. VOC pattern recognition of lung cancer: a comparative evaluation of different dog- and eNose-based strategies using different sampling materials. Acta Oncologica2019;58: 1216–1224.

  2. Amberger, DC, Doraneh-Gard, F, Gunsilius, C., et al. PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood. International Journal of Molecular Sciences2019;20:4590.

Disclosure Information T. Baudrexler: None. T. Boeselt: None. S. Bohlscheid: None. L. Li: None. C. Schmid: None. A. Rank: None. J. Schmohl: None. H.M. Schmetzer: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Modiblast Pharma GmbH, Oberhaching, European Patent 15 801 987.7–1118.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.